Hahnemann Laboratory Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
as on 10-01-2025
- Paid Up Capital ₹ 0.50 M
as on 10-01-2025
- Company Age 4 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Revenue %
(FY 2021)
- Profit 42.79%
(FY 2021)
- Ebitda 42.79%
(FY 2021)
- Net Worth -3.24%
(FY 2021)
- Total Assets -0.06%
(FY 2021)
About Hahnemann Laboratory
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 0.50 M, as per Ministry of Corporate Affairs (MCA) records.
Ritesh Das, Rajarshi Das, and Tapati Das serve as directors at the Company.
- CIN/LLPIN
U24290WB2020PTC236541
- Company No.
236541
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
18 Feb 2020
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Company Details
- Location
Kolkata, West Bengal, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Hahnemann Laboratory?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ritesh Das  | Director | 01-May-2024 | Current |
| Rajarshi Das | Director | 01-May-2024 | Current |
| Tapati Das | Director | 01-Mar-2024 | Current |
Financial Performance of Hahnemann Laboratory.
Hahnemann Laboratory Private Limited, for the financial year ended 2021, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 42.79% increase in profit. The company's net worth dipped by a decrease of 3.24%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Hahnemann Laboratory?
In 2022, Hahnemann Laboratory had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Tapati Domestic Products LlpActive 7 years 11 months
Ritesh Das, Rajarshi Das and 1 more are mutual person
- Jac Olivol Products Private LimitedActive 5 years 2 months
Ritesh Das, Rajarshi Das and 1 more are mutual person
- Hahnemann Laboratory Drugs & Cosmetics Private LimitedActive 2 years 4 months
Ritesh Das, Rajarshi Das and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Hahnemann Laboratory?
Hahnemann Laboratory has a workforce of 9 employees as of Mar 31, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Hahnemann Laboratory, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Hahnemann Laboratory's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
